- Home
- QNCX vs BFRI Comparison
QNCX vs BFRI Comparison
Compare QNCX & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNCX | BFRI |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 16.3M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QNCX | BFRI |
|---|---|---|
| Price | $29.44 | $1.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | N/A | ★ $2.75 |
| AVG Volume (30 Days) | 17.2K | ★ 625.4K |
| Earning Date | 04-10-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.70 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $41,705,000.00 |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $16.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.75 |
| 52 Week Low | $0.08 | $0.57 |
| 52 Week High | $35.41 | $1.66 |
Technical Indicators
Market Signals| Indicator | QNCX | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 55.97 |
| Support Level | $0.82 | $0.78 |
| Resistance Level | $35.38 | N/A |
| Average True Range (ATR) | 2.07 | 0.10 |
| MACD | -1.04 | -0.01 |
| Stochastic Oscillator | 4.41 | 42.81 |
Price Performance
Historical ComparisonAbout QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.